Detailed explanation of the efficacy and role of ivonib

Ivosidenib (Ivosidenib) is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase1 (IDH1) enzyme. It works by reducing the abnormal production of the tumor metabolite 2-hydroxyglutarate (2-HG), thereby leading to the differentiation of malignant cells. Efficacy can be achieved by achieving clinically meaningful remission and/or inhibition of mutant IDH1 enzyme activity using ivosidenib at recommended doses, which are sustainable at recommended doses based on validated methods.

For patients with acute myeloid leukemia, treatment with ivonib extended the time they lived before an event occurred (the treatment no longer worked, the cancer came back, or death), as well as their overall survival. In patients with biliary tract cancer, ivosidenib reduced the risk of disease progression. The prognosis for patients with acute myeloid leukemia and biliary tract cancer is generally poor. The drug's side effects are considered manageable. Manage known risks for heart rhythm problems by limiting medication use to high-risk patients and mitigate the risk of differentiation syndromes by providing educational materials to patients with acute myeloid leukemia.

The original version of ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan, while the price of the original American version sold overseas is as high as more than 200,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.